245 related articles for article (PubMed ID: 29986908)
1. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
2. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.
Mendez JS; Grommes C
Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317
[TBL] [Abstract][Full Text] [Related]
4. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
5. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
Hu BN; Yang X; Yuan YP; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
10. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
11. Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C; Nayak L; Tun HW; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
15. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
17. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system lymphoma with testicular relapse.
Harney J; Pope A; Short SC
Clin Oncol (R Coll Radiol); 2004 May; 16(3):193-5. PubMed ID: 15191006
[TBL] [Abstract][Full Text] [Related]
19. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
20. Improving outcomes in primary CNS lymphoma.
Graham MS; DeAngelis LM
Best Pract Res Clin Haematol; 2018 Sep; 31(3):262-269. PubMed ID: 30213395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]